> I'm not a big fan of any of the current vaccines due to their low efficacy against variants, and especially because they trigger an initially weak immune resp

> I'm not a big fan of any of the current vaccines due to their low efficacy against variants, and especially because they trigger an initially weak immune response and are only effective against symptomatic covid-19. The initial weak immune response gives mutations more time to occur, in my rudimentary understanding. If this vaccine is only good at preventing symptomatic infection- does this mean it'll apply more selective pressure on even more variants? I would assume the average hospitalized case has a longer course than the average non-hospitalized one - in which case, a vaccine that reduces risk of hospitalization seems to also reduce risk of mutations being spread on (since the time for mutations to develop and reproduce in a person is shorter).